Sean Berrier - Rapid Therapeutic VP

All Insiders . USA . 
Stock . Rapid Therapeutic Science . Stakeholders . Insider . Sean Berrier
RTSL Stock  USD 0  0.00  0.00%   

Insider

Sean Berrier is VP of Rapid Therapeutic Science
Phone800 497 6059
Webhttps://www.rtslco.com

Rapid Therapeutic Management Efficiency

The company has return on total asset (ROA) of (0.554) % which means that it has lost $0.554 on every $100 spent on assets. This is way below average. Rapid Therapeutic's management efficiency ratios could be used to measure how well Rapid Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities.
Rapid Therapeutic Science currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 1.13, which is about average as compared to similar companies. Rapid Therapeutic Science has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rapid Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Rapid Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rapid Therapeutic Science sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rapid to invest in growth at high rates of return. When we think about Rapid Therapeutic's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

AC FAAAnteris Technologies
N/A
Hector MartinezBICO Group AB
38
Mikael EngblomBICO Group AB
46
Jason CliftonCellink AB
N/A
Richard GinnTenon Medical
58
Stuart BernsteinBrain Scientific
N/A
Hector MartinezCellink AB
38
Mikael EngblomCellink AB
46
Niclas EmanuelssonBICO Group AB
52
BonnieJeanne GeretyBrain Scientific
61
Daniel CloutierBrain Scientific
57
MPH MDAnteris Technologies
N/A
Jason CliftonBICO Group AB
N/A
Itedale RedwanBICO Group AB
N/A
Irina NazarovaBrain Scientific
N/A
Artur AiraCellink AB
56
Itedale RedwanCellink AB
N/A
Kevin WinterfieldBrain Scientific
N/A
Stephen DenaroAnteris Technologies
N/A
Erica BellBICO Group AB
50
Farid AnthonyBrain Scientific
41
Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc. Rapid Therapeutic operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 8 people. Rapid Therapeutic Science [RTSL] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Asset-0.55

Rapid Therapeutic Science Leadership Team

Elected by the shareholders, the Rapid Therapeutic's board of directors comprises two types of representatives: Rapid Therapeutic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rapid. The board's role is to monitor Rapid Therapeutic's management team and ensure that shareholders' interests are well served. Rapid Therapeutic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rapid Therapeutic's outside directors are responsible for providing unbiased perspectives on the board's policies.
Donal Schmidt, CEO Pres
Duane Drinkwine, Chief Officer
Hughes Watler, CFO Director
Sean Berrier, VP
Frank Gill, Chief Technician
Ryan Johnson, VP Marketing

Rapid Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rapid Therapeutic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset-0.55
Current Valuation13.08 M
Shares Outstanding7.75 M
Shares Owned By Insiders66.33 %
Price To Book136.70 X
Price To Sales193,667 X
Revenue534
Gross Profit334
EBITDA(1.48 M)
Net Income(2.87 M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Rapid Pink Sheet

Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY